PT  - JOURNAL ARTICLE
AU  - Natalia Litvinenko
AU  - Svitlana Cherenko
AU  - Anna Barbova
AU  - Alexandr Ghurilo
TI  - Prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases in Ukraine
DP  - 2013 Sep 01
TA  - European Respiratory Journal
PG  - P2819
VI  - 42
IP  - Suppl 57
4099  - http://erj.ersjournals.com/content/42/Suppl_57/P2819.short
4100  - http://erj.ersjournals.com/content/42/Suppl_57/P2819.full
SO  - Eur Respir J2013 Sep 01; 42
AB  - Fluoroquinolon-resistance in patients with MDR tuberculosis complicate the treatment because adequate second-line regimens are difficult to design. Aim: to study the prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases for right drug providing and prognosis treatment results. Methods. The prevalence of fluoroquinolon-resistance among different MDR TB cases was study in 527 patients, who were treated in Institute during 2009-2012 years. Drug susceptibility test to I and II line TB drugs was performed on liquid media in national reference laboratory with external quality control from Supranational laboratory (Riga, Latvia). Results: All patients had 23 – 46 years old, women was in 233 (44,2 %) cases of them. The XDR was revealed in 127 (24,1 %) patients of them. The fluoroquinolon-resistance excluding XDR cases was revealed in 51 (14,5%) of 400 patients with MDR: in 9 (11,7 %) patients of new cases of MDR (77 patients), in 33 (16,1 %) patients with treatment failure of MDR course (205 patients), in 5 (6,0 %) patients with MDR relapses (84 patients), in 4 (11,8 %) patients of treatment MDR default cases (34 patients). Conclusions. Our investigation demonstrates that the prevalence of fluoroquinolon-resistance in Ukraine corresponds to the world average and is 14,5 % among all cases of MDR. Most fluoroquinolon-resistance was revealed among patients with MDR treatment failure (in 20,3 % patients). The XDR was revealed in 24,1 % cases among patients with MDR TB.